Evidence map›Paper›PMID 29898808›Full record

ArticleBMB reports2018

Facile analysis of protein-protein interactions in living cells by enriched visualization of the p-body.

Miri Choi, Jiyeon Baek, Sang-Bae Han, Sungchan Cho

Open access · goldAbstract read
In one paragraph

Article in BMB reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Miri ChoiAnticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116; College of Pharmacy, Chungbuk National University, Cheongju 28644, South Korea.
Jiyeon BaekAnticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116; College of Pharmacy, Chungbuk National University, Cheongju 28644, South Korea.
Sang-Bae HanCollege of Pharmacy, Chungbuk National University, Cheongju 28644, South Korea.
Sungchan ChoAnticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, South Korea; Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science and Technology, Daejeon 34113, South Korea.
Chungbuk National University · KRKorea Research Institute of Bioscience and Biotechnology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein-Protein Interactions (PPIs) play essential roles in diverse biological processes and their misregulations are associated with a wide range of diseases. Especially, the growing attention to PPIs as a new class of therapeutic target is increasing the need for an efficient method of cell-based PPI analysis. Thus, we newly developed a robust PPI assay (SeePPI) based on the co-translocation of interacting proteins to the discrete subcellular compartment 'processing body' (p-body) inside living cells, enabling a facile analysis of PPI by the enriched fluorescent signal. The feasibility and strength of SeePPI (Signal enhancement exclusively on P-body for Protein-protein Interaction) assay was firmly demonstrated with FKBP12/FRB interaction induced by rapamycin within seconds in real-time analysis of living cells, indicating its recapitulation of physiological PPI dynamics. In addition, we applied p53/MDM2 interaction and its dissociation by Nutlin-3 to SeePPI assay and further confirmed that SeePPI was quantitative and well reflected the endogenous PPI. Our SeePPI assay will provide another useful tool to achieve an efficient analysis of PPIs and their modulators in cells. [BMB Reports 2018; 51(10): 527-532].

Indexed as

Cell SurvivalHeLa CellsHumansImidazolesPiperazinesProtein BindingProtein Interaction MappingProto-Oncogene Proteins c-mdm2SirolimusSubcellular FractionsTacrolimus Binding Protein 1ATumor Suppressor Protein p53Imidazolesnutlin 3PiperazinesProto-Oncogene Proteins c-mdm2SirolimusTacrolimus Binding Protein 1ATumor Suppressor Protein p53

Identifiers

PMID29898808
PMCPMC6235090
OpenAlexW2899369784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.